Human coagulation pathway components

The human coagulation pathway components comprise a complex series of plasma proteins, cofactors, and enzymes that interact in a regulated cascade to achieve hemostasis. This system is traditionally divided into the intrinsic (contact activation), extrinsic (tissue factor), and common pathways, which converge to generate thrombin, the central enzyme that converts soluble fibrinogen into an insoluble fibrin mesh (StatPearls, 2025). Beyond its role in preventing blood loss after vascular injury, dysregulation of these components is a primary driver of thrombotic disorders such as deep vein thrombosis, pulmonary embolism, and stroke (NIH, 2024). Pharmacological intervention in this pathway is a cornerstone of cardiovascular medicine, utilizing anticoagulants that target specific factors like Factor Xa or Thrombin, or broader inhibitors like vitamin K antagonists (Drugs.com, 2024). Modern drug development also focuses on components like Factor XI and XII to decouple thrombosis from hemostasis, aiming to reduce the risk of life-threatening bleeding associated with traditional therapies (AHA Journals, 2019). Overall, the coagulation pathway represents a critical balance between preventing hemorrhage and avoiding pathological clot formation (NIH, 2024).

Other names

Coagulation cascadeBlood clotting pathwayHemostatic systemClotting cascadeBlood coagulation factors

Inhibition of specific clotting factors (e.g., Factor Xa, Thrombin), inhibition of vitamin K-dependent factor synthesis, or promotion of fibrinolysis.